News

Co-Promotion of Repatha ® , EVENITY ® , and BLINCYTO ® to Continue with Astellas Amgen Inc. (Headquarters: Thousand Oaks, California, USA; Chairman and CEO: Robert A. Bradway; “Amgen”), Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Kenji Yasukawa, PhD., “Astellas”), and Amgen Astellas BioPharma K.K. (Headquarters: Tokyo; President and Representative Director: Steve Sugino; “Amgen...

TOKYO, January 17, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the Third Fermentation Building (provisional name) will be constructed as a new manufacturing facility for active pharmaceutical ingredient (API) of Prograf ® (generic name: tacrolimus hydrate*) in the Toyama Technology Center of Astellas Pharma Tech Co., Ltd., a...

- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas’ newly created Genetic Regulation Primary Focus - Natalie C. Holles appointed President and Chief Executive Officer of Audentes TOKYO and San Francisco, January 15, 2020 - Astellas Pharma Inc. (TSE: 4503, President and...

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform - - Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products - TOKYO...